JAK/STAT, and T-bet. In PD-1/PD-L1 immune checkpoint inhibitor cancer treatment, IFN-γ is a prognostic marker. The production of IFN-γ is associated with an improved response to immune ...

Increased ACE2 expression in PTPN2-deficient cells is due to greater signaling in the JAK-STAT pathway in response to inflammatory cytokines such as IFN-γ. Treatment with tofacitinib, a pan-JAK ...